Spleen and Bruton’s tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials
Clinical Hematology International · 24.12.2025 · 7 (4)
DOI: 10.46989/001c.154588 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Hematology International, online erschienen am 24.12.2025. Verfasst von Akhil D Vatvani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, NYC Health + Hospitals/Lincoln, Bronx, New York, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Spleen tyrosine kinase (SYK) and Bruton’s tyrosine kinase (BTK) inhibitors have emerged as promising targeted therapies for adult immune thrombocytopenia (ITP). However, a comprehensive synthesis of their benefits compared to placebo has not been previously conducted. This study aims to analyze the efficacy and safety of SYK and BTK inhibitors in comparison to placebo for the treatment of adult patients with ITP. A systematic search was performed across four major databases (Medline, Europe PMC, Scopus, and ClinicalTrials.gov) for randomized controlled trials (RCTs) evaluating SYK and/or BTK inhibitors versus placebo in adults with ITP. We utilized random-effects models to evaluate the risk ratio (RR) and mean difference (MD) for the occurrence of outcomes. Five RCTs across four publications were included. Both SYK and BTK inhibitors significantly improved overall platelet response (RR 3.95; 95%CI: 2.68 – 5.81, p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, NYC Health + Hospitals/Lincoln, Bronx, New York, USA.
- Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, 15811, Indonesia.
ORCID-Profile: Akhil D Vatvani, Timotius I Hariyanto, Alejandrina C Ramirez, Nehad Shabarek
Zitieren
APA
Vatvani, A. D., Hariyanto, T. I., Ramirez, A. C., & Shabarek, N. (2025). Spleen and Bruton’s tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. Clinical Hematology International, 7(4). https://doi.org/10.46989/001c.154588
Vancouver
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N. Spleen and Bruton’s tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. Clinical Hematology International. 2025;7(4). doi:10.46989/001c.154588
BibTeX
@article{Vatvani2025,
author = {Vatvani, Akhil D and Hariyanto, Timotius I and Ramirez, Alejandrina C and Shabarek, Nehad},
title = {Spleen and Bruton’s tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials},
journal = {Clinical Hematology International},
year = {2025},
volume = {7},
number = {4},
doi = {10.46989/001c.154588}
}
EUVIMED